应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
09969 诺诚健华
未开盘 09-29 16:08:04
14.470
+0.370
+2.62%
最高
14.840
最低
14.000
成交量
779.28万
今开
14.100
昨收
14.100
日振幅
5.96%
总市值
255.68亿
流通市值
216.18亿
总股本
17.67亿
成交额
1.13亿
换手率
0.52%
流通股本
14.94亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
诺诚健华盘中涨超5% 近日与礼来签署研发合作及授权许可协议
新浪港股 · 09-29 10:50
诺诚健华盘中涨超5% 近日与礼来签署研发合作及授权许可协议
港股异动 | 诺诚健华(09969.HK)早盘涨超5% 近期与礼来签订重磅协议 公司出海更进一步
智通财经 · 09-29 10:00
港股异动 | 诺诚健华(09969.HK)早盘涨超5% 近期与礼来签订重磅协议 公司出海更进一步
异动解读｜诺诚健华盘中上涨5.18%，礼来33.5亿美元重磅合作持续发酵
行情直击 · 09-29 09:55
异动解读｜诺诚健华盘中上涨5.18%，礼来33.5亿美元重磅合作持续发酵
瑞银：诺诚健华维持“买入”评级 目标价21.80港元
新浪港股 · 09-27 12:28
瑞银：诺诚健华维持“买入”评级 目标价21.80港元
瑞银：诺诚健华(09969)与礼来(LLY.US)就创新靶点项目达成合作 看法正面
智通财经 · 09-25
瑞银：诺诚健华(09969)与礼来(LLY.US)就创新靶点项目达成合作 看法正面
潜在总额33.5亿美元，股价跌幅超10% 诺诚健华牵手礼来后股价“过山车”
每日经济新闻 · 09-24
潜在总额33.5亿美元，股价跌幅超10% 诺诚健华牵手礼来后股价“过山车”
诺诚健华牵手礼来（LLY）达成新药合作 交易总额最高33.5亿美元
金吾财讯 · 09-24
诺诚健华牵手礼来（LLY）达成新药合作 交易总额最高33.5亿美元
诺诚健华（688428）披露子公司与礼来公司签署研发合作及授权许可协议，9月24日股价下跌10.6%
证券之星 · 09-24
诺诚健华（688428）披露子公司与礼来公司签署研发合作及授权许可协议，9月24日股价下跌10.6%
9月24日诺诚健华跌10.60%，富国精准医疗混合A基金重仓该股
证券之星 · 09-24
9月24日诺诚健华跌10.60%，富国精准医疗混合A基金重仓该股
港股异动 | 诺诚健华(09969)冲高后再度跳水 现跌幅超10% 诺诚健华与礼来达成33.5亿美元合作
智通财经 · 09-24
港股异动 | 诺诚健华(09969)冲高后再度跳水 现跌幅超10% 诺诚健华与礼来达成33.5亿美元合作
生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖
金吾财讯 · 09-24
生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖
港A异动丨诺诚健华AH股午后拉升，全资子公司与礼来签署授权许可协议
格隆汇 · 09-24
港A异动丨诺诚健华AH股午后拉升，全资子公司与礼来签署授权许可协议
诺诚健华：全资子公司与礼来签署授权许可协议，协议包含至多32.5亿美元的里程碑付款
老虎资讯综合 · 09-24
诺诚健华：全资子公司与礼来签署授权许可协议，协议包含至多32.5亿美元的里程碑付款
诺诚健华：全资子公司与礼来签署授权许可协议，协议包含至多32.5亿美元的里程碑付款
格隆汇 · 09-24
诺诚健华：全资子公司与礼来签署授权许可协议，协议包含至多32.5亿美元的里程碑付款
异动解读｜诺诚健华盘中下跌5.02%，报14.96港元
行情直击 · 09-24
异动解读｜诺诚健华盘中下跌5.02%，报14.96港元
股市必读：诺诚健华新发布《港股公告：2026年中期报告》
证券之星 · 09-23
股市必读：诺诚健华新发布《港股公告：2026年中期报告》
诺诚健华（688428）披露2026年中期报告，9月22日股价上涨5.12%
证券之星 · 09-22
诺诚健华（688428）披露2026年中期报告，9月22日股价上涨5.12%
诺诚健华2026年中期营收11.37亿元，经调整净利润2.77亿元
公告速递 · 09-22
诺诚健华2026年中期营收11.37亿元，经调整净利润2.77亿元
诺诚健华涨7.33%，长城国瑞证券三周前给出“买入”评级
证券之星 · 09-21
诺诚健华涨7.33%，长城国瑞证券三周前给出“买入”评级
港股异动 | 创新药概念股全线爆发 据报美国拟放宽药企授权许可合作 创新药BD估值有望修复
智通财经 · 09-21
港股异动 | 创新药概念股全线爆发 据报美国拟放宽药企授权许可合作 创新药BD估值有望修复
暂无数据
公司概况
公司名称：
诺诚健华
所属市场：
SEHK
上市日期：
--
主营业务：
诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-B05、ICP-332、ICP-488、ICP-192、ICP-723、ICP-033和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫疾病。该公司还在开发用于治疗由T细胞功能异常所导致的自身免疫性疾病的产品。该公司在国内和国外市场开展业务。
发行价格：
--
{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":14.47,"timestamp":1790669284009,"preClose":14.1,"halted":0,"volume":7792750,"delay":0,"changeRate":0.026241134751773122,"floatShares":1494000000,"shares":1767000000,"eps":0.4443897999215378,"marketStatus":"未开盘","change":0.37,"latestTime":"09-29 16:08:04","open":14.1,"high":14.84,"low":14,"amount":112699421,"amplitude":0.059574,"askPrice":14.47,"askSize":10000,"bidPrice":14.46,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":0.5910127060651236,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790731800000},"marketStatusCode":0,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":14.1,"openAndCloseTimeList":[[1790645400000,1790654400000],[1790658000000,1790668800000]],"volumeRatio":0.7025657771570599,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":28.88,"timestamp":1790665200000,"preClose":28.63,"halted":0,"volume":12428000,"delay":0,"premium":"-57.16"}},"requestUrl":"/m/hq/s/09969/tweets","defaultTab":"tweets","newsList":[{"id":"2671262791","title":"诺诚健华盘中涨超5% 近日与礼来签署研发合作及授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2671262791","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671262791?lang=zh_cn&edition=full","pubTime":"2026-09-29 10:50","pubTimestamp":1790650200,"startTime":"0","endTime":"0","summary":"模拟交易客户端诺诚健华盘中涨超5%。诺诚健华近日宣布与礼来签署研发合作及授权许可协议，诺诚健华与礼来双方将在创新药物研发领域开展战略合作，诺诚健华将依托专有药物发现平台及深厚的研究经验，发现并开发至多5项创新性靶点项目，以解决重大未满足的临床需求。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-29/doc-initnfqh2546504.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","688428","09969","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671264485","title":"港股异动 | 诺诚健华(09969.HK)早盘涨超5% 近期与礼来签订重磅协议 公司出海更进一步","url":"https://stock-news.laohu8.com/highlight/detail?id=2671264485","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671264485?lang=zh_cn&edition=full","pubTime":"2026-09-29 10:00","pubTimestamp":1790647236,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09969","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182930465","title":"异动解读｜诺诚健华盘中上涨5.18%，礼来33.5亿美元重磅合作持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1182930465","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182930465?lang=zh_cn&edition=full","pubTime":"2026-09-29 09:55","pubTimestamp":1790646952,"startTime":"0","endTime":"0","summary":"9月29日，诺诚健华盘中上涨5.18%，报14.83港元/股，成交额2767.18万港元。此前该股在公布与礼来合作后连续回调，本次反弹或与市场重新定价合作价值有关。消息面上，诺诚健华于9月24日宣布与礼来签署研发合作及授权许可协议，总交易金额最高达33.5亿美元，其中首付款及近期里程碑付款最高1亿美元，潜在研发及商业化里程碑付款约32.5亿美元，另有个位数百分比分级特许权使用费。诺诚健华将依托自有药物发现平台开发至多5项创新靶点项目。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"诺诚健华上涨，礼来33.5亿美元合作发酵","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670410470","title":"瑞银：诺诚健华维持“买入”评级 目标价21.80港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670410470","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670410470?lang=zh_cn&edition=full","pubTime":"2026-09-27 12:28","pubTimestamp":1790483280,"startTime":"0","endTime":"0","summary":"热点栏目自选股\n数据中心\n行情中心\n资金流向\n模拟交易客户端瑞银发布研报称，维持诺诚健华（09969）“买入”评级及目标价21.8港元。诺诚健华与礼来（LLY.US）就发现及开发最多5个创新靶点项目达成合作，该行对此持正面看法，认为属于对公司研发能力的认可。该行指出，预付款及近期里程碑付款合计1亿美元，潜在研发及商业里程碑付款达32.5亿美元，并可获得净销售额单位数百分比分层权利金。据管理层表示，所有项目均由药物发现阶段开始。相关付款或为2026年收入及净利润带来上行空间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-09-27/doc-initftkn0360074.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["EWH","09969","688428"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670449487","title":"瑞银：诺诚健华(09969)与礼来(LLY.US)就创新靶点项目达成合作 看法正面","url":"https://stock-news.laohu8.com/highlight/detail?id=2670449487","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670449487?lang=zh_cn&edition=full","pubTime":"2026-09-25 17:06","pubTimestamp":1790327211,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银发布研报称，维持诺诚健华(09969)“买入”评级及目标价21.8港元。诺诚健华与礼来(LLY.US)就发现及开发最多5个创新靶点项目达成合作，该行对此持正面看法，认为属于对公司研发能力的认可。该行指出，预付款及近期里程碑付款合计1亿美元，潜在研发及商业里程碑付款达32.5亿美元，并可获得净销售额单位数百分比分层权利金。据管理层表示，所有项目均由药物发现阶段开始。相关付款或为2026年收入及净利润带来上行空间。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","09969","BK0239","688428","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669449587","title":"潜在总额33.5亿美元，股价跌幅超10% 诺诚健华牵手礼来后股价“过山车”","url":"https://stock-news.laohu8.com/highlight/detail?id=2669449587","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669449587?lang=zh_cn&edition=full","pubTime":"2026-09-24 21:17","pubTimestamp":1790255851,"startTime":"0","endTime":"0","summary":"9月24日，诺诚健华（SH688428）A股收盘价29.86元/股，日跌幅10.60%。消息面上，公司当日中午宣布与礼来公司达成战略研究合作及许可协议，下午开盘后先直线拉升，股价创出历史新高，达到35元/股。之后，股价又快速回落。根据公告，诺诚健华与礼来的交易总金额可观，最高可达33.5亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609243883899191.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609243883899191.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","09969","BK0239","688428","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669441461","title":"诺诚健华牵手礼来（LLY）达成新药合作 交易总额最高33.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2669441461","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669441461?lang=zh_cn&edition=full","pubTime":"2026-09-24 18:09","pubTimestamp":1790244579,"startTime":"0","endTime":"0","summary":"金吾财讯 | 两家公司周四宣布，诺诚健华与礼来（LLY）达成研究合作及授权协议，携手开展新药开发。诺诚健华将借助自身药物发现平台与研发实力，针对至多五个靶点筛选并推进候选化合物。根据协议，诺诚健华有资格获取最高1亿美元的预付款及近期付款；若达成开发、商业化相关目标，还可拿到最高32.5亿美元里程碑付款。此外，诺诚健华还将按照产品年度净销售额，收取个位数分级特许权使用费。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/OTc4NDY1YzgwYTY5ZDI5OGQwMTAxMzU2NDM1Mjg5Ng==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/OTc4NDY1YzgwYTY5ZDI5OGQwMTAxMzU2NDM1Mjg5Ng==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"306428","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0640476718.USD","LU0316494557.USD","IE00BJJMRY28.SGD","LU2023250504.SGD","LU2750360997.AUD","VHT","LU1712237335.SGD","LU2462157665.USD","LU1983299246.USD","IE00BN29S564.USD","LU0174119429.USD","LU0109391861.USD","LU0158827948.USD","LU0889565916.HKD","IE00B1XK9C88.USD","PJP","LU1366192091.USD","LU0345770308.USD","CANC","LU1127390331.HKD","LU1145028129.USD","LU2361044865.SGD","LU2896262040.SGD","LU2471134952.CNY","LU2491050071.SGD","SG9999001176.USD","LU0354030438.USD","LU0432979614.USD","LU1804176565.USD","SGXZ31699556.SGD","LU0823434740.USD","LLY","LU1551013425.SGD","LU2168564495.EUR","LU2063271972.USD","LU2357305700.SGD","LU0683600562.USD","LU0786609619.USD","LU1069344957.HKD","LU1691799644.USD","LU1323610961.USD","IHE","LU2264538146.SGD","LU2361044949.HKD","LU0823416689.USD","LU0256863902.USD","IE00BJT1NW94.SGD","IE00BKDWB100.SGD","IXJ","LU0353189680.USD","TRUH","IYH","THNR","LU2552382215.SGD","IE00B2B36J28.USD","LU1629891620.HKD","BK4533","LU0353189763.USD","LU0882574139.USD","LU2028103732.USD","LU2168564149.EUR","LU1023059063.AUD","LU0225283273.USD","LU0466842654.USD","IE00B4JS1V06.HKD","LU1868836591.USD","SGXZ51526630.SGD","LU1868836914.USD","LU2468319806.SGD","LU0471298777.SGD","SG9999014880.SGD","SG9999018857.SGD","LU0058720904.USD","LU2237443622.USD","LU0943347566.SGD","MEDI","SGXZ99366536.SGD","LU0823434583.USD","IE00BWXC8680.SGD","IE00BFSS7M15.SGD","LU0234572021.USD","IE0001KFT4U8.USD","LU0106261372.USD","LU1720051108.HKD","LU2023251221.USD","LU2112291526.USD","LU0079474960.USD","IE00B775H168.HKD","SG9999017495.SGD","LU1093756325.SGD","LU1280957306.USD","LU2324357040.USD","LU2746668974.SGD","BK4534","LU2461242641.AUD","LU1064131342.USD","LU2237438978.USD","LU2236285917.USD","LU0094547139.USD","PPH","LU1868837300.USD","OZEM","LU1232071149.USD","LU0456855351.SGD","SG9999013999.USD","LU0096364046.USD","LU0820561818.USD","688428","SG9999014906.USD","BK4599","LU0109394709.USD","LU0417517546.SGD","LU2552382058.USD","LU0203202063.USD","LU0964807845.USD","LU1061106388.HKD","LU1551013342.USD","LU2746668461.USD","LU2089984988.USD","LU0471298694.HKD","SG9999001176.SGD","LU1035775433.USD","XLV","LU2237443465.HKD","LU2237443549.SGD","SG9999015986.USD","SG9999014898.SGD","AGNG","09969","LU0238689110.USD","LU1623119135.USD","IE00BJJMRX11.SGD","IE0004445239.USD","LU0385154629.USD","BK4581","HRTS","IE00BFTCPJ56.SGD","LU2168564065.EUR","LU2360106947.USD","LU2265009873.SGD","LU2271345857.HKD","LU2602419157.SGD","GB00BDT5M118.USD","LU2552382132.HKD","SGXZ57979304.SGD","SGXZ81514606.USD","LU2237443382.USD","LU0256863811.USD","LU2237443895.HKD","LU2491050154.USD","BK4516","LU2456880835.USD","LU1057294990.SGD","LU0689472784.USD","IE00BK4W5L77.USD","GDOC","LU1868837136.USD","MEDX","LU1267930730.SGD","LLYX","LU1979441026.SGD","IE0002141913.USD","LU2023250330.USD","LU0006306889.USD","LU2108987350.USD","IE00BJJMRZ35.SGD","LU2213496289.HKD","LU2491049909.HKD","JDOC","LU0354030511.USD","LU0672654240.SGD","LU2471134796.USD","RXL","BK1161","LU1988902786.USD","SG9999015945.SGD","LU1720051017.SGD","BK4585","LU0820562030.AUD","LU0266013472.USD","LU2168563687.JPY","LU2361045086.USD","SG9999015978.USD","LU1989771016.USD","LU0097036916.USD","FTXH","LU0122379950.USD","LU0320765992.SGD","LU2471134879.HKD","TMED","LU0708995401.HKD","LLII","LU2087625088.SGD","LU0133085943.USD","IE0009355771.USD","LU1868836757.USD","SG9999018865.SGD","BK1574","LU2089283258.USD","LU2417539215.USD","LU0320765059.SGD","WDNA","LU2756315664.SGD","MHIP","LU2462591350.SGD","LU0203201768.USD","FHLC","LU0882574055.USD","LU0289739699.SGD","LU1291159041.SGD","LU1917777945.USD","IE00BFSS8Q28.SGD","LU1814569148.SGD","IE0005OL40V9.USD","LU2089284900.SGD","LU2237443978.SGD","IE00B7KXQ091.USD","IE00BKPKM429.USD","LU0061475181.USD","LLYZ","LU0323591593.USD","LU1548497426.USD","ILDR","LU0198837287.USD","LU0820561909.HKD","LU2756315318.SGD","IE00B1BXHZ80.USD","LU2211815571.USD","SG9999014914.USD","ELIL","LU0787776722.HKD","BK4588","SG9999015952.SGD","LU0345770993.USD","CURE","IE0004445015.USD","LU2168564222.USD","LU2471134523.USD","IE00BK4W5M84.HKD","LU1093756168.USD","LU2106854487.HKD","LU0114720955.EUR","IE00B4R5TH58.HKD","LU0158827781.USD","LU2111349929.HKD","BK4007","LU0210536198.USD","LU2750360641.GBP","ELIS","IE00BJLML261.HKD","LU1974910355.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669466701","title":"诺诚健华（688428）披露子公司与礼来公司签署研发合作及授权许可协议，9月24日股价下跌10.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669466701","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669466701?lang=zh_cn&edition=full","pubTime":"2026-09-24 17:36","pubTimestamp":1790242617,"startTime":"0","endTime":"0","summary":"近日，诺诚健华医药有限公司发布《关于子公司与礼来公司签署研发合作及授权许可协议的公告》。公告显示，公司全资子公司北京诺诚健华医药科技有限公司与Eli Lilly and Company签署研发合作及授权许可协议，双方将在创新药物研发领域开展战略合作，共同发现并开发至多5项创新性靶点项目。协议自2026年9月24日起生效，持续至所许可产品的特许权使用费支付期限结束。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400030450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","09969","688428","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669463195","title":"9月24日诺诚健华跌10.60%，富国精准医疗混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669463195","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669463195?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:38","pubTimestamp":1790239137,"startTime":"0","endTime":"0","summary":"证券之星消息，9月24日诺诚健华跌10.60%创60日新高，收盘报29.86元，换手率11.09%，成交量30.32万手，成交额9.51亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共35家，其中持有数量最多的公募基金为富国基金的富国精准医疗混合A。富国精准医疗混合A目前规模为28.98亿元，最新净值3.368，较上一交易日上涨0.24%，近一年下跌3.06%。富国精准医疗混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400028553.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688428","BK0239","BK1574","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669256451","title":"港股异动 | 诺诚健华(09969)冲高后再度跳水 现跌幅超10% 诺诚健华与礼来达成33.5亿美元合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2669256451","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669256451?lang=zh_cn&edition=full","pubTime":"2026-09-24 13:38","pubTimestamp":1790228331,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺诚健华午间发布重磅合作公告，午后开盘跌幅快速收窄至不足1%，但后续再度跳水跌幅扩大逾10%10%。消息面上，9月24日，诺诚健华宣布与礼来签署研发合作及授权许可协议，双方将在创新药物研发领域开展战略合作，诺诚健华将依托专有药物发现平台及深厚的研究经验，发现并开发至多5 项创新性靶点项目，以解决重大未满足的临床需求。根据协议条款，礼来公司将向诺诚健华支付最高1亿美元的首付款和近期里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1500343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4588","KCAI","BK1161","688428","09969","VXUS","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669451177","title":"生物医药板块全线走低 诺诚健华（09969）跌10.48% 机构指行业需求尚未明显回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2669451177","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669451177?lang=zh_cn&edition=full","pubTime":"2026-09-24 13:36","pubTimestamp":1790228201,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股生物医药板块午后全线走低，截至发稿，诺诚健华 跌10.48%，荣昌生物跌7.99%，复宏汉霖跌7.68%，康诺亚-B跌5.86%，再鼎医药跌5.32%，君实生物跌4.53%，金斯瑞生物科技跌4.21%，康方生物跌3.54%，科伦博泰生物跌3.11%，泰格医药跌2.35%，药明生物跌1.80%，百济神州跌1.56%，药明合联跌1.12%。消息面上，国盛证券发布研报称，医药行业需求尚未明显回暖，降本增效、费用精细化管理已成为利润端的重要支撑。下半年关注流感旺季带来的阶段性需求催化。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZTUyNTQ0NjcxODUwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1992441","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548","LU0828237510.HKD","LU0348825331.USD","161726","09995","LU1961090484.USD","BK1141","09926","02696","02268","09688","399441","BK1576","688428","KURE","LU0856984785.SGD","LU2328871848.SGD","LU3063872942.SGD","SG9999002562.SGD","LU0516422366.SGD","LU0561508036.HKD","BK4581","LU2039709279.SGD","LU0348783233.USD","LU2399975544.HKD","LU1242518931.SGD","SG9999014674.SGD","01877","02269","LU0456846285.SGD","03347","LU1242518857.USD","XBI","LU0540923850.HKD","BK1515","HK0000306701.USD","02162","LU1770034418.SGD","06160","09969","LU1303224171.USD","LU1719994722.HKD","BK1583","LU0516423174.USD","LU0140636845.USD","LU0348766576.USD","LU1880383366.USD","SG9999002463.SGD","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669592034","title":"港A异动丨诺诚健华AH股午后拉升，全资子公司与礼来签署授权许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2669592034","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669592034?lang=zh_cn&edition=full","pubTime":"2026-09-24 13:04","pubTimestamp":1790226295,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688428","09969","BK0239","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139274839","title":"诺诚健华：全资子公司与礼来签署授权许可协议，协议包含至多32.5亿美元的里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1139274839","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139274839?lang=zh_cn&edition=full","pubTime":"2026-09-24 12:08","pubTimestamp":1790222882,"startTime":"0","endTime":"0","summary":"9月24日，诺诚健华公告，公司的全资子公司北京诺诚健华医药科技有限公司与Eli Lilly and Company签署研发合作及授权许可协议，双方将在创新药物研发领域开展战略合作，公司将依托专有药物发现平台及深厚的研究经验，发现并开发至多5项创新性靶点项目，以解决重大未满足的临床需求。礼来公司将向公司支付最高1亿美元的首付款和近期里程碑付款。潜在的研发及商业化里程碑付款总额合计约32.5亿美元。此外，公司有权按许可产品年度净销售额收取个位数百分比的分级特许权使用费。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺诚健华：全资子公司与礼来签署授权许可协议，协议包含至多32.5亿美元的里程碑付款","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969","ELIL","LLY","LLII","ELIS","688428","LLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669458456","title":"诺诚健华：全资子公司与礼来签署授权许可协议，协议包含至多32.5亿美元的里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2669458456","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669458456?lang=zh_cn&edition=full","pubTime":"2026-09-24 12:06","pubTimestamp":1790222812,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","BK0239","09969","688428","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141220824","title":"异动解读｜诺诚健华盘中下跌5.02%，报14.96港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1141220824","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1141220824?lang=zh_cn&edition=full","pubTime":"2026-09-24 11:44","pubTimestamp":1790221443,"startTime":"0","endTime":"0","summary":"9月24日，诺诚健华盘中下跌5.02%，报14.96港元/股，成交额7061.02万港元。诺诚健华所在的生物科技行业中，个股普遍走弱，其中信达生物跌2.61%，康方生物跌3.74%，百济神州跌1.28%，荣昌生物跌6.79%，映恩生物-B跌6.51%。诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司，专注于肿瘤和自身免疫性疾病等存在未满足临床需求的领域，主要产品管线包括奥布替尼、坦昔妥单抗等，在国内和国外市场开展业务。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669129065","title":"股市必读：诺诚健华新发布《港股公告：2026年中期报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2669129065","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669129065?lang=zh_cn&edition=full","pubTime":"2026-09-23 02:09","pubTimestamp":1790100550,"startTime":"0","endTime":"0","summary":"截至2026年9月22日收盘，诺诚健华报收于32.0元，上涨5.12%，换手率6.5%，成交量17.77万手，成交额5.59亿元。当日关注点交易信息汇总：9月22日主力资金净流出453.45万元，游资资金净流出4021.64万元，散户资金净流入4475.09万元。公司公告汇总：诺诚健华发布2026年中期报告，报告期内实现总收益113.71亿元，同比增长55.5%，现金及等价物达84.3亿元，实现盈利。多项临床试验取得积极进展，全球化战略稳步扩展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300002517.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","688428","BK1574","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669061140","title":"诺诚健华（688428）披露2026年中期报告，9月22日股价上涨5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669061140","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669061140?lang=zh_cn&edition=full","pubTime":"2026-09-22 22:18","pubTimestamp":1790086703,"startTime":"0","endTime":"0","summary":"截至2026年9月22日收盘，诺诚健华报收于32.0元，较前一交易日上涨5.12%，最新总市值为566.3亿元。该股当日开盘30.1元，最高32.32元，最低30.09元，成交额达5.59亿元，换手率为6.5%。近日，诺诚健华发布2026年中期报告，报告期内实现总收益113.71亿元，同比增长55.5%。公司现金及等价物达84.3亿元，盈利质量改善并实现盈利。多项临床试验取得积极进展，全球化战略稳步扩展。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200041672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","09969","BK1161","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104117189","title":"诺诚健华2026年中期营收11.37亿元，经调整净利润2.77亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1104117189","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104117189?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:46","pubTimestamp":1790066774,"startTime":"0","endTime":"0","summary":"诺诚健华于近日发布2026年中期业绩。期内，公司实现营收约11.37亿元，同比上涨55.5%。经调整净利润约2.77亿元，而上年同期为亏损约0.16亿元，实现同比扭亏为盈。公司表示，营收增长主要受多元化产品组合持续拓展及已有产品市场渗透率提升推动。从成本结构看，销售及分销开支约2.69亿元，同比上涨10.3%；研发开支约4.97亿元，同比上涨10.5%；行政开支约1.12亿元，同比提升18.4%。上半年经营活动净现金流为0.81亿元。上述财报并未披露下个财报期的具体业绩指引。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"诺诚健华2026年中期营收11.37亿元，经调整净利润2.77亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669159968","title":"诺诚健华涨7.33%，长城国瑞证券三周前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2669159968","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669159968?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:42","pubTimestamp":1789980149,"startTime":"0","endTime":"0","summary":"今日诺诚健华涨7.33%，收盘报30.44元。2026年8月31日，长城国瑞证券研究员胡晨曦发布了对诺诚健华的研报《药品收入持续高增，自免管线兑现在即》，该研报对诺诚健华给出“买入”评级。因此，我们维持其“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为国海证券的孔维崎、周小刚。诺诚健华个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100020919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688428","161027","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669139135","title":"港股异动 | 创新药概念股全线爆发 据报美国拟放宽药企授权许可合作 创新药BD估值有望修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139135","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669139135?lang=zh_cn&edition=full","pubTime":"2026-09-21 13:43","pubTimestamp":1789969421,"startTime":"0","endTime":"0","summary":"意味着新规不会一刀切封禁全部生物医药跨境交易，肿瘤ADC、双抗等常规抗癌创新药，允许海外药企收购管线、开展授权BD合作。中信建投指出，2026年世界肺癌大会中，中国创新药在肺癌领域全面发力，多个项目从早期探索迈入III期临床与全球化阶段。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498535.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2778985437.USD","LU0634319403.HKD","BK4585","LU2476274308.USD","LU1720050803.USD","LNGR","LU0326950275.SGD","LU2097828474.EUR","BK1587","BK4588","HK0000165453.HKD","LU1961090484.USD","IE00B5MMRT66.SGD","159992","09926","LU0348735423.USD","BK1589","LU0417516571.SGD","KURE","LU0149534421.HKD","06978","LU2476274720.SGD","01801","LU0561508036.HKD","LU2097828631.EUR","LU1831875114.USD","LU0455707207.USD","LU0348784397.USD","BK1161","LU2399975544.HKD","LU0502904849.HKD","LU2242644610.SGD","MEDX","LU0244354667.USD","LU1794554557.SGD","LU1969619763.USD","IE00B543WZ88.USD","BK1574","LU2488822045.USD","02162","09969","LU0348767384.USD","VXUS","BK1583","LU2097828714.EUR","LU0348766576.USD","KCAI","LU0417516738.SGD","IBBQ","IE00BPRC5H50.USD"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":-0.0742},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.2201},{"period":"6month","weight":-0.0677},{"period":"1year","weight":-0.1825},{"period":"ytd","weight":0.1764}],"compareEarnings":[{"period":"1week","weight":-0.0225},{"period":"1month","weight":-0.0415},{"period":"3month","weight":0.0718},{"period":"6month","weight":-0.0236},{"period":"1year","weight":-0.0789},{"period":"ytd","weight":-0.0432}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-B05、ICP-332、ICP-488、ICP-192、ICP-723、ICP-033和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫疾病。该公司还在开发用于治疗由T细胞功能异常所导致的自身免疫性疾病的产品。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.103999},{"month":2,"riseRate":0.666667,"avgChangeRate":0.128923},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.010195},{"month":4,"riseRate":0.714286,"avgChangeRate":0.102464},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.059233},{"month":6,"riseRate":0.857143,"avgChangeRate":0.113731},{"month":7,"riseRate":0.571429,"avgChangeRate":0.05509},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.06378},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.019347},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.033299},{"month":11,"riseRate":0.833333,"avgChangeRate":0.100833},{"month":12,"riseRate":0.5,"avgChangeRate":-0.012645}],"exchange":"SEHK","name":"诺诚健华","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,09969,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}